Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Recruiting · NCT06021678 · Registry updated 2025-02-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma | CD20-positive Non-Hodgkin Lymphoma | Recruiting | Phase 1 / Phase 2 | 2025-02-27 | NCT06021678 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangzhou Excelmab Inc. | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital Affiliated to Zhengzhou University, Henan Cancer Hospital | Zhengzhou | China | 1 |
| Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences | Tianjin | China | 1 |
| Qilu Hospital, Cheeloo College of Medicine, Shandong University | Jinan | China | 1 |
| Shanghai Sixth People's Hospital, Shanghai Jiaotong University school of Medicine | Shanghai | China | 1 |